Listing 1 - 7 of 7 |
Sort by
|
Choose an application
Nurses --- Prescriptions --- Electronic Prescribing --- Medical Informatics Applications
Choose an application
Despite electronic prescribing, medication errors are still occurring in hospitals. The pharmaceutical analysis of electronic prescriptions, also called « validation », is expected to improve and secure the use of medicines. Objective: This study analyses the performance of the pharmaceutical validation of the electronic prescriptions using a checklist defining of the minimum criteria to analyze per prescription. Methods: On the basis of literature, legislation, observations and focus groups, a checklist that includes the minimum criteria for a valid electronic prescription was developed and validated by a Delphi method. A prospective multicenter study (3 hospitals) compared the performance of pharmaceutical validation five days before and five days after introduction of this checklist. Comparison was made on pertinence (rate of acceptance of the interventions made by the pharmacist to correct medication errors), efficacy (number of patients having interventions), efficiency (acceptance of interventions compared to lime spent for validation) and productivity (number of patients having interventions compared to lime spent for validation). In addition, users' satisfaction about the checklist was evaluated. Results After two rounds of the Delphi method, a validated checklist has been written out. Eleven pharmacists participated in the study. Pertinence, efficacy, efficiency and productivity did not improve significantly due to the use of the checklist (respective p-values= 0,072, 0,717, 1,000 and 0,788). However, the eleven pharmacists are globally satisfied with this checklist. Conclusion: A standardized checklist is an interesting strategy to homogenize the pharmaceutical validation of the electronic prescriptions but not sufficient to improve the performance of the validation. It should be further investigated alongside other strategies. The ultimate objective of pharmaceutical validation of prescriptions is to improve the quality of care of hospitalized patients.
Checklist --- Electronic Prescribing --- Pharmacy Service, Hospital
Choose an application
Choose an application
Electronic prescribing (EP) is a complex discipline, the success of which relies on the successful interplay of system design, data support and clinical practice. It represents the use of electronic systems to facilitate and enhance communication of a prescription or medicine order, and improves legibility and completeness of prescriptions, improves availability of electronic decision support tools at the point of prescribing, enables a comprehensive audit trail, and reduces medication-related errors. These benefits are far-reaching in significance, both in terms of their effects on risk management and risk reduction and their financial impact. Given the likely growth of interest in electronic medicines management, this discussion of relevant design issues and their impact is timely. Electronic Prescribing: Principles and Practice discusses the basic principles of the design and implementation of secondary care electronic medicine management systems, and how they impact hospital workflow and clinical practice. It documents the key aspects of EP systems for use in secondary care, including design issues, data support, benefits and the ways in which electronic medicines management systems can optimize clinical and professional practice.Because of the significance of electronic medicines management to the whole medical supply chain, and the various stakeholders involved in the IT implementations, the book will be of interest to a wide range of professionals, from hospital pharmacists and prescribing physicians to health system managers and informaticians.
Medicine & Public Health. --- Health Informatics. --- Medicine/Public Health, general. --- Public Health/Gesundheitswesen. --- General Practice / Family Medicine. --- Nursing. --- Medicine. --- Family medicine. --- Medical records --- Médecine --- Médecine familiale --- Dossiers médicaux --- Soins infirmiers --- Data processing. --- Informatique --- Drugs --Prescribing --Data processing. --- Drugs --- Medical Order Entry Systems --- Electronic Prescribing --- Medical Records Systems, Computerized --- Hospital Information Systems --- Prescriptions --- Management Information Systems --- Pharmaceutical Services --- Information Systems --- Hospital Administration --- Medical Records --- Organization and Administration --- Medical Informatics Applications --- Records as Topic --- Health Services --- Health Services Administration --- Medical Informatics --- Health Care Facilities, Manpower, and Services --- Health Care --- Information Science --- Pharmacy, Therapeutics, & Pharmacology --- Health & Biological Sciences --- Data processing --- Prescribing --- Medicaments --- Medications --- Medicine (Drugs) --- Medicines (Drugs) --- Pharmaceuticals --- Prescription drugs --- General practice (Medicine). --- Public health. --- Health informatics. --- Public Health. --- Bioactive compounds --- Medical supplies --- Pharmacopoeias --- Chemotherapy --- Materia medica --- Pharmacology --- Pharmacy --- Clinical sciences --- Medical profession --- Human biology --- Life sciences --- Medical sciences --- Pathology --- Physicians --- EHR systems --- EHR technology --- EHRs (Electronic health records) --- Electronic health records --- Electronic medical records --- EMR systems --- EMRs (Electronic medical records) --- Information storage and retrieval systems --- Clinical nursing --- Nurses and nursing --- Nursing process --- Care of the sick --- Medicine --- Family practice (Medicine) --- General practice (Medicine) --- Physicians (General practice) --- Medical care --- Health Workforce --- Community health --- Health services --- Hygiene, Public --- Hygiene, Social --- Public health services --- Public hygiene --- Social hygiene --- Health --- Human services --- Biosecurity --- Health literacy --- Medicine, Preventive --- National health services --- Sanitation --- Clinical informatics --- Health informatics --- Medical information science --- Information science
Choose an application
Polypharmacy is a necessary and important aspect of drug treatment; however, it becomes a challenge when the medication risks outweigh the benefits for an individual patient. Drug–drug interactions and the introduction of prescribing cascades are common features of polypharmacy, which can lead to ineffectiveness and increased risk of adverse drug reactions (ADR). Genes encoding CYP450 isozymes and other drug-related biomarkers have attracted considerable attention as targets for pharmacogenetic (PGx) testing due to their impact on drug metabolism and response. This Special Issue is devoted to explore the status and initiatives taken to circumvent ineffectiveness and to improve medication safety for polypharmacy patients. Specific areas include drug–drug interactions and consequences thereof in therapeutic management, including PK- and PD-profiling; the application of PGx-based guidance and/or decision tools for drug–gene and drug–drug gene interactions; medication reviews; development and application of deprescribing tools; and drivers and barriers to overcome for successful implementation in the healthcare system.
Medicine --- Pharmaceutical industries --- acute kidney injury --- early biomarker --- plasma neutrophil gelatinase-associated lipocalin --- soluble urokinase plasminogen activator receptor --- medication optimization --- older patients --- emergency department --- multimorbidity --- polypharmacy --- potentially inappropriate medication use --- older adults --- prevalence --- determinants --- chronic --- outpatient --- 2019 Beers criteria --- Ethiopia --- pharmacogenomics --- persons with diabetes --- drug–drug interactions --- drug–gene interactions --- cytochrome P450 --- SLCO1B1 --- drug interaction checkers --- adverse drug reactions --- pharmacogenetics --- personalized medicine --- phenprocoumon --- DOACs --- bleeding --- thromboembolism --- HLA --- drug hypersensitivity --- abacavir --- allopurinol --- flucloxacillin --- antiepileptic drugs --- cost-effectiveness --- shared medication record --- medication reconciliation --- drug information service --- hospital pharmacy service --- electronic prescribing --- electronic medical record --- clinical pharmacist --- CYP2D6 --- CYP2D7P --- CYP2D8P --- copy number variation --- CNV --- genotyping --- 5’nuclease assay --- HRM --- high resolution melting --- drug metabolization --- extracellular vesicles --- exosomes --- microvesicles --- pharmacogene expression --- medication review --- deprescriptions --- quality of life --- aged --- aged, 80 and over --- nursing homes --- deprescribing --- medication-based risk score --- health outcomes --- cytochromes --- CYP1A2 --- adverse drug reaction --- antipsychotics --- olanzapine --- clozapine --- loxapine --- children --- youth --- digital decision-support --- health services research --- general practice --- process evaluation --- antidepressants --- utility --- population-based --- appropriateness --- medication adherence --- digital health
Choose an application
Polypharmacy is a necessary and important aspect of drug treatment; however, it becomes a challenge when the medication risks outweigh the benefits for an individual patient. Drug–drug interactions and the introduction of prescribing cascades are common features of polypharmacy, which can lead to ineffectiveness and increased risk of adverse drug reactions (ADR). Genes encoding CYP450 isozymes and other drug-related biomarkers have attracted considerable attention as targets for pharmacogenetic (PGx) testing due to their impact on drug metabolism and response. This Special Issue is devoted to explore the status and initiatives taken to circumvent ineffectiveness and to improve medication safety for polypharmacy patients. Specific areas include drug–drug interactions and consequences thereof in therapeutic management, including PK- and PD-profiling; the application of PGx-based guidance and/or decision tools for drug–gene and drug–drug gene interactions; medication reviews; development and application of deprescribing tools; and drivers and barriers to overcome for successful implementation in the healthcare system.
acute kidney injury --- early biomarker --- plasma neutrophil gelatinase-associated lipocalin --- soluble urokinase plasminogen activator receptor --- medication optimization --- older patients --- emergency department --- multimorbidity --- polypharmacy --- potentially inappropriate medication use --- older adults --- prevalence --- determinants --- chronic --- outpatient --- 2019 Beers criteria --- Ethiopia --- pharmacogenomics --- persons with diabetes --- drug–drug interactions --- drug–gene interactions --- cytochrome P450 --- SLCO1B1 --- drug interaction checkers --- adverse drug reactions --- pharmacogenetics --- personalized medicine --- phenprocoumon --- DOACs --- bleeding --- thromboembolism --- HLA --- drug hypersensitivity --- abacavir --- allopurinol --- flucloxacillin --- antiepileptic drugs --- cost-effectiveness --- shared medication record --- medication reconciliation --- drug information service --- hospital pharmacy service --- electronic prescribing --- electronic medical record --- clinical pharmacist --- CYP2D6 --- CYP2D7P --- CYP2D8P --- copy number variation --- CNV --- genotyping --- 5’nuclease assay --- HRM --- high resolution melting --- drug metabolization --- extracellular vesicles --- exosomes --- microvesicles --- pharmacogene expression --- medication review --- deprescriptions --- quality of life --- aged --- aged, 80 and over --- nursing homes --- deprescribing --- medication-based risk score --- health outcomes --- cytochromes --- CYP1A2 --- adverse drug reaction --- antipsychotics --- olanzapine --- clozapine --- loxapine --- children --- youth --- digital decision-support --- health services research --- general practice --- process evaluation --- antidepressants --- utility --- population-based --- appropriateness --- medication adherence --- digital health
Choose an application
Polypharmacy is a necessary and important aspect of drug treatment; however, it becomes a challenge when the medication risks outweigh the benefits for an individual patient. Drug–drug interactions and the introduction of prescribing cascades are common features of polypharmacy, which can lead to ineffectiveness and increased risk of adverse drug reactions (ADR). Genes encoding CYP450 isozymes and other drug-related biomarkers have attracted considerable attention as targets for pharmacogenetic (PGx) testing due to their impact on drug metabolism and response. This Special Issue is devoted to explore the status and initiatives taken to circumvent ineffectiveness and to improve medication safety for polypharmacy patients. Specific areas include drug–drug interactions and consequences thereof in therapeutic management, including PK- and PD-profiling; the application of PGx-based guidance and/or decision tools for drug–gene and drug–drug gene interactions; medication reviews; development and application of deprescribing tools; and drivers and barriers to overcome for successful implementation in the healthcare system.
Medicine --- Pharmaceutical industries --- acute kidney injury --- early biomarker --- plasma neutrophil gelatinase-associated lipocalin --- soluble urokinase plasminogen activator receptor --- medication optimization --- older patients --- emergency department --- multimorbidity --- polypharmacy --- potentially inappropriate medication use --- older adults --- prevalence --- determinants --- chronic --- outpatient --- 2019 Beers criteria --- Ethiopia --- pharmacogenomics --- persons with diabetes --- drug–drug interactions --- drug–gene interactions --- cytochrome P450 --- SLCO1B1 --- drug interaction checkers --- adverse drug reactions --- pharmacogenetics --- personalized medicine --- phenprocoumon --- DOACs --- bleeding --- thromboembolism --- HLA --- drug hypersensitivity --- abacavir --- allopurinol --- flucloxacillin --- antiepileptic drugs --- cost-effectiveness --- shared medication record --- medication reconciliation --- drug information service --- hospital pharmacy service --- electronic prescribing --- electronic medical record --- clinical pharmacist --- CYP2D6 --- CYP2D7P --- CYP2D8P --- copy number variation --- CNV --- genotyping --- 5’nuclease assay --- HRM --- high resolution melting --- drug metabolization --- extracellular vesicles --- exosomes --- microvesicles --- pharmacogene expression --- medication review --- deprescriptions --- quality of life --- aged --- aged, 80 and over --- nursing homes --- deprescribing --- medication-based risk score --- health outcomes --- cytochromes --- CYP1A2 --- adverse drug reaction --- antipsychotics --- olanzapine --- clozapine --- loxapine --- children --- youth --- digital decision-support --- health services research --- general practice --- process evaluation --- antidepressants --- utility --- population-based --- appropriateness --- medication adherence --- digital health
Listing 1 - 7 of 7 |
Sort by
|